Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
58% PTCs presented a genetic alteration either RET/PTC rearrangement, BRAF V599E mutation or both: three cases of PTCs (25%) presented a RET/PTC rearrangement; three cases of PTCs (25%) presented a BRAF V599E mutation and in one case (8%) both alterations were identified.
|
15859312 |
2005 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Papillary thyroid carcinomas in humans are associated with the ret/PTC oncogene and, following loss of p53 function, may progress to anaplastic carcinomas.
|
10934169 |
2000 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PTC with RET/PTC rearrangement as well as the TPC-1 cell line (the only one harboring RET/PTC rearrangement) did not show the BRAF(V599E) mutation.
|
12881714 |
2003 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid carcinomas are associated with nonoverlapping activating mutations of RET, NTRK, RAS and BRAF, which altogether are present in approximately 70% of cases.
|
16551863 |
2006 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PTC is associated with gene rearrangements generating RET/PTC and TRK oncogenes, and to the BRAFV600E activating point mutation.
|
21339735 |
2011 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid carcinoma (PTC) generally shows an excellent prognosis except in cases with aggressive backgrounds or clinicopathological features.
|
29349484 |
2018 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid carcinoma (PTC) and medullary thyroid carcinoma (MTC) are characterized by genomic rearrangements and point mutations in the proto-oncogene RET.
|
29436694 |
2018 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
RET mutations cause several human diseases such as papillary thyroid carcinoma, multiple endocrine neoplasia types 2A and 2B, and Hirschsprung's disease.
|
11544105 |
2001 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ret gene transcripts and protein were found in all PTC variants as well as in their corresponding metastases.
|
11579677 |
2001 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET was rearranged in 52% of microcarcinomas, a statistically significant higher frequency than that found previously in clinically evident PTCs using the same technique.
|
11742034 |
2001 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
RET is also found mutated in sporadic medullary thyroid cancer (MTC) and rearranged in sporadic papillary thyroid carcinomas.
|
11746981 |
2001 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET/PTC rearrangements are believed to be tumor-initiating events in papillary thyroid carcinomas.
|
14555660 |
2003 |
Papillary thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
RET oncogene expression of papillary thyroid carcinoma in Korea.
|
15170542 |
2004 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET is the oncogene that causes papillary thyroid carcinoma and medullary thyroid carcinoma.
|
15331579 |
2004 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
RET/PTC is a transforming sequence created by the fusion of the tyrosine kinase domain of the RET protooncogene with the 5' end of the locus D10S170 designated by probe H4 and is frequently found activated in human papillary thyroid carcinomas.
|
1542652 |
1992 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET/PTC1 and RET/PTC3 are the markers for papillary thyroid carcinoma.
|
15502856 |
2004 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET/PTC expression and BRAF mutations were mutually exclusive.
|
16402937 |
2006 |
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
RET rearrangements in post-Chernobyl papillary thyroid carcinomas with a short latency analysed by interphase FISH.
|
16641909 |
2006 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.
|
17210721 |
2007 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET-associated PTC tumors are phenotypically indolent and relatively less aggressive than RET-related MTCs.
|
19487296 |
2009 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET/PTC, Ras, and receptor tyrosine kinase could dually activate the PI3K/Akt and MAPK pathways.
|
20578891 |
2010 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rearranged during transfection (RET)/papillary thyroid carcinoma (PTC) gene rearrangements are one of the major genetic alterations found in papillary thyroid carcinoma.
|
24957039 |
2014 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, BRAF (B-RAF proto-oncogene, serine/threonine kinase) gene mutations, RAS (rat sarcoma) mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the known pathways playing a crucial role in the development of thyroid cancer.
|
25789503 |
2015 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET/PTC rearrangement is the most common genetic modification identified in this category of cancer, increasing proliferation and dedifferentiation by the activation of the RET/PTC-RAS-BRAF-MAPK-ERK signaling pathway.
|
27314338 |
2016 |
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET is activated, as RET/PTC oncogene, by somatic rearrangements which link the TK domain to a constitutive dimerization interface in papillary thyroid carcinomas.
|
8570194 |
1995 |